The Transformative Role of PET/CT Molecular Imaging in Alzheimer’s Disease
June is recognized worldwide as Alzheimer’s & Brain Awareness Month. This international initiative provides an ideal opportunity to highlight the latest scientific advances in the diagnosis and management of neurodegenerative diseases.
Today, PET/CT molecular imaging represents one of the most powerful tools available to the medical community, transforming dementia from an “invisible” clinical diagnosis into a visible, biologically documented reality.
Among the most important brain changes associated with Alzheimer’s disease (AD) are:
Reduced ability of the brain to metabolize glucose, its primary source of energy.
Accumulation of the protein fragment beta-amyloid into clusters known as amyloid plaques outside neurons and other brain cells.
Accumulation of an abnormal form of the tau protein within neurons.
Additional pathological changes include neuroinflammation and brain atrophy (loss of brain volume).
In neurodegenerative disorders such as Alzheimer’s disease, alterations in synaptic activity occur early in the disease process, often before structural brain changes can be detected by conventional imaging techniques. In this context, PET molecular imaging using specialized radiopharmaceuticals plays a crucial role in identifying these early pathological changes.
PET Radiopharmaceuticals in Alzheimer’s Disease
18F-FDG PET
18F-FDG PET is considered a marker of neurodegeneration and disease progression.
In 2004, the U.S. Food and Drug Administration (FDA) approved FDG-PET imaging for patients with recently developed dementia who met the diagnostic criteria for Alzheimer’s disease (AD) or frontotemporal dementia (FTD), enabling differentiation between these conditions based on their distinct metabolic patterns.
The rationale for FDG-PET imaging in Alzheimer’s disease is based on the reduction in cerebral metabolic activity associated with the disease. Brain PET imaging with 18F-FDG demonstrates decreased glucose metabolism resulting from reduced neuronal metabolism and synaptic activity in regions undergoing neurodegeneration due to excessive amyloid deposition.
FDG-PET is recommended to support the early diagnosis of:
Mild Cognitive Impairment (MCI) due to Alzheimer’s disease
Dementia with Lewy Bodies (DLB)
Frontotemporal Lobar Degeneration (FTLD)
Amyloid PET
Amyloid PET has become a critical diagnostic tool in Alzheimer’s disease because it enables the non-invasive detection of amyloid plaques, one of the hallmark neuropathological features of the disease.
PET imaging of cerebral amyloid deposition has been available in research settings for more than two decades and has received approval for clinical use from the FDA, the European Medicines Agency (EMA), and other regulatory authorities worldwide.
Three amyloid PET radiopharmaceuticals have received FDA approval:
18F-Florbetapir (2012)
18F-Flutemetamol (2013)
18F-Florbetaben (2014)
These tracers are approved for imaging neuritic beta-amyloid plaques in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease.
Importantly, all three agents have subsequently received significant label updates from the FDA, allowing their use in patient selection and treatment monitoring for the new anti-amyloid therapies, including lecanemab and donanemab.
Tau PET (18F-Flortaucipir)
Tau PET is an advanced molecular neuroimaging technique that enables the detection and mapping of tau protein pathology in the brain.
Under normal conditions, tau protein plays an essential role in maintaining neuronal structure. In several neurodegenerative disorders, however, tau becomes abnormally phosphorylated and aggregates into neurofibrillary tangles that damage brain cells.
In 2020, the FDA approved the first tau PET radiopharmaceutical, 18F-Flortaucipir, for imaging tau neurofibrillary tangles in the brain.
18F-Flortaucipir PET/CT enables the in vivo visualization of tau pathology. While amyloid accumulation begins many years before clinical symptoms appear, tau accumulation correlates closely with disease staging, neurodegeneration, and the rate of cognitive decline.
In patients with Mild Cognitive Impairment (MCI), a positive Tau PET scan is considered a strong predictor of future cognitive deterioration.
The Importance of Early Diagnosis
Alzheimer’s & Brain Awareness Month highlights the critical importance of early diagnosis through molecular imaging.
The combined use of FDG-PET, Amyloid PET, and Tau PET/CT allows the detection of Alzheimer’s disease during its pre-symptomatic stages, fundamentally changing patient management and facilitating access to innovative therapies.
The newly approved disease-modifying immunotherapies are effective primarily during the earliest stages of the disease, namely:
Mild Cognitive Impairment
Mild Alzheimer’s dementia
Delayed diagnosis may deprive patients of the opportunity to receive treatments capable of slowing disease progression.
Early intervention helps preserve synaptic density and prolongs the period during which patients can maintain their independence and quality of life.
A New Era in Alzheimer’s Disease Diagnosis
Alzheimer’s disease is no longer a diagnosis based solely on clinical suspicion and observation of symptoms. Modern PET/CT molecular imaging has transformed the way clinicians approach the disease by enabling direct visualization of the biological mechanisms underlying its development.
Through FDG-PET, Amyloid PET, and Tau PET, clinicians can now detect pathological brain changes years before severe cognitive decline becomes apparent.
At a time when the first disease-modifying therapies are becoming a reality, accurate and timely diagnosis has become more important than ever. Identifying patients in the earliest stages of disease not only improves therapeutic planning but also provides the opportunity to preserve functionality, autonomy, and quality of life for a longer period.
Alzheimer’s & Brain Awareness Month reminds us that awareness, prevention, and early diagnosis remain our most powerful weapons against this disease. PET molecular imaging does more than illuminate the brain—it illuminates the path toward a new era in dementia care, where early intervention can meaningfully alter disease progression and improve the future of patients and their families.